Hepatitis C News and Research

Latest Hepatitis C News and Research

Hepatitis C virus rarely transmitted through sex between monogamous heterosexuals

Individuals infected by the hepatitis C virus (HCV) have nothing to fear from sex in a monogamous, heterosexual relationship. Transmission of HCV from an infected partner during sex is rare according to new research published in the March issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD).

19 Mar 2013

Weekend reading: Humanizing hospitals, splurge of health data and huge sodas

Every week reporter Ankita Rao selects interesting reading from around the Web.

15 Mar 2013

Researchers determine way to predict and protect against new strains of flu virus

Researchers have determined a way to predict and protect against new strains of the flu virus, in the hope of improving immunity against the disease.

13 Mar 2013

Trans-Pacific Partnership (TPP) Agreement: an interview with Judit Rius, Médecins Sans Frontières

The Trans-Pacific Partnership (TPP) is a trade deal currently being negotiated between eleven countries of the Asia-Pacific region: Australia, Brunei Darussalam, Canada, Chile, Malaysia, Mexico, New Zealand, Peru, United States, Singapore and Vietnam.

12 Mar 2013

Melittin-loaded nanoparticles can destroy human immunodeficiency virus

Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of Medicine in St. Louis have shown.

8 Mar 2013

HIV might promote aging and disease progression in people with HCV, study results suggest

Infectious disease experts at Johns Hopkins have found that among people infected with the hepatitis C virus, co-infection with HIV, speeds damage and scarring of liver tissue by almost a decade.

5 Mar 2013

Express Scripts finds decline in 2012 U.S. spending on traditional prescription drugs

For the first time in more than 20 years, there was a decrease in 2012 U.S. spending on traditional prescription drugs — primarily pills people take to treat more common diseases such as high cholesterol and high blood pressure — according to new data released today by Express Scripts.

5 Mar 2013

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).

5 Mar 2013

HIV infection may increase risk of acute myocardial infarction

A study that analyzed data from more than 82,000 veterans suggests that infection with the human immunodeficiency virus (HIV) was associated with an increased risk of acute myocardial infarction (AMI, heart attack) beyond what is explained by recognized risk factors, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

4 Mar 2013

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

1 Mar 2013

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

At the Faculty of Pharmacy of the Basque Public University (UPV/EHU) the Pharmacokinetics, Nanotechnology and Gene Therapy research team is using nanotechnology to develop new formulations that can be applied to drugs and gene therapy.

1 Mar 2013

Stem cell line could also advance research into liver cancers, cystic fibrosis

Chronic or acute, liver failure can be deadly. Toxins take over, the skin turns yellow and higher brain function slows. "There is no effective therapy at the moment to deal with the toxins that build up in your body," said Neil Talbot, a Research Animal Scientist for the USDA Agricultural Research Service. "Their only option now is to transplant a liver."

1 Mar 2013

State roundup: Health care industry calls drug testing bill in N.H. 'vague'

Representatives from the health care industry said Tuesday they have a vested interest in stopping employees from stealing controlled substances but a bill being considered by New Hampshire lawmakers to drug test their workers is too vague. The proposal is part of the legislative response to a recent scandal at Exeter Hospital, where an employee allegedly stole drugs and replaced them with Hepatitis C infected syringes later used on patients.

28 Feb 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

NanoViricides retires Series C Convertible Preferred Stock previously purchased by Seaside

NanoViricides, Inc., announced today that it has retired the remainder of the Series C Convertible Preferred Stock previously purchased by Seaside 88, LP, with a cash payment.

27 Feb 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Govs brace for impact of scheduled cuts in home states

The nation's governors met in Washington over the weekend, and among their hottest topics: a White House warning regarding the state-by-state impact of sequestration, which is scheduled to kick in March 1.

26 Feb 2013

Wnt-induced Lgr5 expression marks stem cell production in the liver

For decades scientists around the world have attempted to regenerate primary liver cells known as hepatocytes because of their numerous biomedical applications, including hepatitis research, drug metabolism and toxicity studies, as well as transplantation for cirrhosis and other chronic liver conditions. But no lab in the world has been successful in identifying and growing liver stem cells in culture -- using any available technique - until now.

26 Feb 2013

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.

25 Feb 2013

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Hepatitis C virus rarely transmitted through sex between monogamous heterosexuals

Weekend reading: Humanizing hospitals, splurge of health data and huge sodas

Researchers determine way to predict and protect against new strains of flu virus

Trans-Pacific Partnership (TPP) Agreement: an interview with Judit Rius, Médecins Sans Frontières

Melittin-loaded nanoparticles can destroy human immunodeficiency virus

HIV might promote aging and disease progression in people with HCV, study results suggest

Express Scripts finds decline in 2012 U.S. spending on traditional prescription drugs

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

HIV infection may increase risk of acute myocardial infarction

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

Stem cell line could also advance research into liver cancers, cystic fibrosis

State roundup: Health care industry calls drug testing bill in N.H. 'vague'

EpiCept fourth quarter revenue decreases to $0.1 million

NanoViricides retires Series C Convertible Preferred Stock previously purchased by Seaside

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Govs brace for impact of scheduled cuts in home states

Wnt-induced Lgr5 expression marks stem cell production in the liver

Okairos to commence novel RSV vaccine Phase I clinical trial

Janssen submits simeprevir regulatory application in Japan to treat HCV

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in